Previous 10 | Next 10 |
Thinly traded nano cap Aytu BioScience (NASDAQ: AYTU ) jumps 322% premarket on robust volume in reaction to its license agreement with L.B. Resources Limited for the exclusive distribution of a point-of-care rapid test for COVID-19 IgG/IgM antibodies in the U.S. for three years...
Company Expects to Pursue Commercial Use Under FDA's Emergency Use Authorization ENGLEWOOD, CO / ACCESSWIRE / March 10, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announc...
Are These Penny Stocks On Your Watch List? Are you looking for penny stocks to buy ? Or maybe you’re simply looking to learn about some trending penny stocks to watch right now. No matter what camp you’re in, you’ve come to the right place. We’ve built a track reco...
Aytu BioScience Enters Consumer Healthcare Market with a Portfolio of Over 35 Products that Generated $24M in Revenue During Past Four Quarters Combination Creates Specialty Rx and Consumer Pharma Company with LTM Revenue of Approximately $43M ENGLEWOOD, CO & SAN DIEGO, CA / AC...
Aytu BioScience, Inc. (AYTU) Q2 2020 Earnings Conference Call February 13, 2020 4:30 PM ET Company Participants Josh Disbrow – Chairman and Chief Executive Officer Dave Green – Chief Financial Officer Conference Call Participants Carl Byrnes – Northland S...
Aytu BioScience (NASDAQ: AYTU ): Q2 GAAP EPS of -$0.01 beats by $0.25 . More news on: Aytu BioScience, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
ENGLEWOOD, CO / ACCESSWIRE / February 13, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant medical needs, today will provide an overview of its business, including the company's operational and f...
ENGLEWOOD, CO / ACCESSWIRE / February 6, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that the company will present its operational results for the quarter ende...
ENGLEWOOD, CO / ACCESSWIRE / February 5, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced the acceptance of scientific abstracts reporting the findings from two Nat...
Aytu and Innovus Shareholder Meetings to Approve Merger Scheduled for February 13, 2020 ENGLEWOOD, CO & SAN DIEGO, CA / ACCESSWIRE / January 27, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address sign...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...